AMA rejects call to ban DTC

21 June 2001

The House of Delegates of the American Medical Association has rejectedcalls for it to petition the US Food and Drug Administration to ban direct-to-consumer advertising of prescription drugs (Marketletter June 25).

However, the organization has called for all DTC ads for prescription drugs to state that: "your physician may recommend other appropriate treatments." AMA spokesmen said that, while the Association would ask pharmaceutical manufacturers to add this disclaimer voluntarily, it would also be seeking legislation to require its inclusion, reports Reuters Health.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight